Monoclonal antibodies and progressive multifocal leukoencephalopathy

Canadian Journal of Neurological Sciences

Volumn 38, Issue 4, 2011, Pages 565-571

  Keene, Daniel ^a   Legare, Carole ^a   Taylor, Elaine ^a   Gallivan, Jim ^a   Cawthorn, Gloria ^a   Vu, Duc ^a  

^a Marketed Biologicals Biotechnology and Natural Health Products Bureau   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; BEVACIZUMAB; CETUXIMAB; DACLIZUMAB; ECULIZUMAB; EFALIZUMAB; GOLIMUMAB; IBRITUMOMAB TIUXETAN; INFLIXIMAB; NATALIZUMAB; OKT 3; OMALIZUMAB; PANITUMUMAB; RANIBIZUMAB; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

CANADA; DRUG EXPOSURE; DRUG INDICATION; HUMAN; JC VIRUS; NONHUMAN; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REGISTER; REVIEW; RISK BENEFIT ANALYSIS; WORLD HEALTH ORGANIZATION; DRUG SURVEILLANCE PROGRAM; FACTUAL DATABASE; IMMUNOLOGY; PATHOGENICITY; STATISTICS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIBODIES, MONOCLONAL; CANADA; DATABASES, FACTUAL; HUMANS; IMMUNOLOGIC FACTORS; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL;

EID: 80053312105     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100012105     Document Type: Review

References (59)

1. Psaty B, Burke S. Protecting the Health of the Public-Institute of Medicine recommendations on drug safety. N Eng J Med. 2006 (17);315:1753-5.
2. Talbot J, Nilsson B. Pharmacovigilance in the pharmaceutical industry. Br J Clin Pharmacol. 1998;45(5):427-31.
3. Simon L. Pharmacovigilance: towards a better understanding of the benefit to risk ratio. Ann Rheum Dis. 2002 Nov;61 Suppl 2: ii88-9.
4. Fletcher A. Spontaneous adverse drug reaction reporting vs event monitoring: a comparison. J R Soc Med. 1991;84(6):341-4.
5. Koralnik I. Progressive multifocal Leukoencephalopathy revisited: has the disease outgrown its name? Ann Neurol. 2006;60(2): 162-73.
6. Major E. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Ann Rev Med. 2010;61:35-47.
7. Berger J. Progressive multifocal leukoencephalopathy. Curr Neurol Neurosc Rep. 2007;7:461-9.
8. Khalili K, White M, Lublin F et al . Reactivation of JC virus and development of PML in patients with multiple sclerosis. Neurology. 2007;68(13):985-90.
9. AksamitA. Review of progressive multifocal leukoencephalopathy and natalizumab. Neurologist. 2006;12(6):293-8.
10. Berger J, Houff S. Progressive multifocal leukoencephalopathy: lessons from AIDS and natalizumab. Neurol Res. 2006;28(3): 299-305.
11. Carson K, Focosi D, Major E, et al. Monoclonal antibodyassociated progressive multifocal leucoencephalopathy in patients treated with rituximab, natilizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol. 2009;10(8):816-24.
12. Martin S, Marty F, Fiumara K, Treon S, Gribben J, Baden L. Infectious complications associated with alemtuzumab use in lymphoproliferative disorders. Clin Infect Dis. 2006;43(1): 16-24.
13. Jiang M, Abend J, Johnson S, Imperiale M. The role of polyomaviruses in human disease. Virology. 2009;384(2):266-73.
14. Khalili K, Gordon J, White M. The polyomavirus, JC and its involvement in human disease. Adv Exp Med Biol. 2006;577: 274-87.
15. Major E, Amemiya K, Tornatore C, Houff S, Berger J. Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev. 1992;5(1):49-73.
16. Sweet T, Del Valle L, Kalili K. Molecular biology and immunoregulation of human neurotropic JC virus in CNS. J Cell Physiol. 2002;191(3):249-56.
17. Agostini H, Ryschkewitsch C, Stoner G. Genotype profile of human polyomavirus JC excreted in urine of immunocompetent individuals. J Clin Microbiol. 1996;34(1):159-64.
18. Walker D, Padgett B. The epidemiology of human polyomavirus. Prog Clin Biol. Res. 1983;105:99-106.
19. Knowles W. Discovery and epidemiology of human polyomaviruses BK virus (BKV) and JC virus (JCV).Adv Exp Med Biol. 2006;577:19-45.
20. Seth P, Diaz F, Major E. Advances in the biology of JC virus and induction of progressive multifocal leukoencephalopathy. J NeuroVirol. 2003;9(2):236-46.
21. Mori M, Aoki N, Shimada H, Tajima M, Kato K. Detection of JC virus in the brains of aged patients without progressive multifocal leukoencephalopathy by the polymerase chain reaction and Southern hybridication analysis. Neurosci Lett. 1992;141(2):151-5.
22. Perez-Liz G, Del Valle L, Gentilella A, Croul S, Khalili K. Detection of JC virus DNA fragments but not proteins in normal brain tissue. Ann Neurol. 2008;64(4):379-87.
23. White F, Ishaq M, Stoner G, Frisque R. JC virus DNA is present in many human brain samples from patients without progressive multifocal leukoencephalopathy. J Virol. 1992; 66(10):5726-34.
24. Newman J, Frisque R. Identification of JC virus variants in multiple tissues of pediatric and adult PML patients. JMed Virol. 1999;58 (1):79-86.
25. Debue S, Branchetti E, Berolacci S et al. JC virus VP1 loop-specific polymorphisms are associated with favourable prognosis for progressive multifocal leukoencephalopathy. J Neurovirol. 2009; 15(1):51-6.
26. Dubois V, Dutronic H, Lafon M, et al . Latency and reactivation of JC virus in peripheral blood of human immunodeficiency virus type1-infected patients. J Clin Microbiol. 1997;35(9):2288-92.
27. Bartt R. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy. Curr Opin Neurol. 2006;19(4): 341-9.
28. Clifford D, Del A, Simpson D, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lesions from 28 cases. Lancet Neurol. 2010:9(4):438-46.
29. Hartung H. New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol. 2009;8(1):28-9.
30. Langer-Gould A, Atlas S, Green A, Bollen A, Pelletier D. Progressive multifcoal leukoencephalopathy in a patient treated with natalizumab. N Eng J Med. 2005;353(4):375-81.
31. Kleinschmidt-DeMasters B, Tyler B. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Eng JMed. 2005; 353(4):369-74.
32. Linda H, von Heijne A, Major E, et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Eng J Med. 2009;361(11):1081-7.
33. Major E. Reemergence of PML in natalizumab-treated patientsnew cases, same concerns. N Eng J Med. 2009;36 (11)1:1041-3.
34. Yousry T, Major E, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Eng J Med. 2006;354(9):924-33.
35. Wenning W, Haghikia A, Laudenberger J, et al. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Eng J Med. 2009;361(11):1075-80.
36. van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Eng J. Med. 2005;353(4):362-8.
37. Boren E, Cheema G, Naguma S, Anasari A, Gershwin E. The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J Autoimmun. 2008;30(1-2):90-8.
38. Carson K, Evens A, Richey E, et al. Progressive multifocal leukoencephalopathy after rutixmab therapy in HIV-negative patients: a report of 57 cases from the Research onAdverse Drug Events and Reports project. Blood. 2009;113(20):4834-40.
39. D'Souza A, Wilson J, Mukherjee S, Jaiyesimi I. Progressive multifocal leukoencephalopathy in chronic lymphocytes leukemia: a report of three cases and review of the literature. Clinical Lymph Myeloma Leuk. 2010;10(1):E1-9.
40. Fleischmann R. Progressive multifocal leukoencephalopathy following rutiximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum. 2009;60(11):3225-8.
41. Harris H. Progressive multifocal leucoencephalopathy in a patient with systemic lupus erythematosus treated with rituximab. Rheumatology (Oxford). 2008;47(2):225-6.
42. Hopfinger G, Plessl A, Grisold W, et al. Progressive multifocal leukoencepatholopathy after rituximab in a patient with relapsed follicular lymphoma and low IgG levels and a low CD4+ lymphocyte count. Leuk Lymphoma. 2008;49(12):2367-9.
43. Kranick S, Mowry E, Rosenfeld M. Progressive multifocal leukoencephalopathy after rituxamab in case of non-Hodgkin lymphoma. Neurology. 2007;9(24):704-6.
44. Matteucci P, Magni M, Di Nicola M, Carlo-Stella C, Uberti C, Gianni A. Leukoencephalopathy and papavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody. Blood. 2002;100(3):1104.
45. Ram R, Ben-Bassat I, Shipilberg O, Polliack A, Raanani P. The late adverse events of rituximab therapy-rare but there! Leuk Lymphoma. 2009;50(7):1083-95.
46. Freim Wahl S, Folvik M, Torp S. Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission after treatment with cystostatics and rituxuamb: a case report and review of the literature. Clin Neuropathol. 2007;26 (2):68-73.
47. Yokoyama H, Watanabe T, Maruyama D, Kim S, Kobayashi Y, Tobinai K. Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy: a case report and review of the literature. Int J Hematol. 2008;88(4):443-7.
48. Waggoner J, Martinu T, Palmer S. Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant. J Heart Lung Transplant. 2009;28(4): 395-8.
49. Uppenkamp M, EngertA, Deihl V, Bunjes D, Huhn D, Brittinger G. Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high and low-grade non-Hodgkin's lymphoma: a multicenter phase I/II study. Ann Hematol. 2002;81(1):26-32.
50. Korman B, Tyler K, Korman N. Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression. A cautionary tale for dermatologists. Arch Dermatol. 2009;145(8): 937-42.
51. Malloy E, Calabrese L. Therapy: targeted but not trouble-free: efalizumab and PML. Nat Rev Rheumatol. 2009;5(8):418-19.
52. Mohan N, Edwards E, Cupps T, et al. Demyelination occurring during anti-tumor necrosis factor α therapy for inflammatory arthritides. Arthritis Rheum. 2001;44(12):2862-9.
53. Wu J, Fung M, Kwong K, Hornbuckle K, Muniz E. Postmarketing drug safety surveillance. Pharm Dev Regul. 2003;1(4):231-44.
54. http://www.hc-sc.gc.ca/dhp-mps/medeff/advisoriesavis/public/-2009/ raptiva-2-pc-cp-eng.php.
55. Garcia-Suarez J, Miguel D, Krsnik I, Banas H, Arribas I, Burgaleta C. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies. Am J Hematol. 2005;80(4): 271-81.
56. Cid J, Revilla M, Cervera A, et al. Progressive multifocal leukoencephalopathy following oral fludarabine treatment with chronic lymphocytic leukemia. Ann Haematol. 2000; 9(7): 391-5.
57. http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/public/-2007/ rituxan-4-pc-cp-eng.php.
58. Berger J, Houff S, Major E. Monoclonal antibodies and progressive multifocal leukoencephalopathy. MAbs. 2009;1(16):583-9.
59. Terenant D, Painfond G. Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther. 2005;5 Suppl 1:S37-47.